Study of an experimental drug during breast-conserving surgery for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests an experimental drug given during surgery to remove breast cancer. The goal is to see if it helps prevent the cancer from coming back in people with triple-negative breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with triple-negative breast cancer (a type of breast cancer that tests negative for estrogen, progesterone, and HER2 receptors).
- Your cancer is at stage II or III (but not inflammatory breast cancer).
- You are planning to have breast-conserving surgery (lumpectomy) to remove the cancer.
- You have not had chemotherapy or other systemic treatment before surgery (neoadjuvant therapy).
- You do not have any other cancer (except treated skin cancer or cervical cancer in situ) in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
This trial tests a combination of two drugs given before surgery for early-stage triple-negative breast cancer. The goal is to see if this treatment can shrink tumors and improve outcomes while possibly reducing the need for more intensive treatment.
This study compares a new drug (JS004) added to an immunotherapy and chemotherapy combination versus the usual immunotherapy plus chemotherapy or chemotherapy alone. It aims to see if adding this new drug can shrink breast cancer more effectively before surgery.
This trial is testing whether giving a combination of two medicines before surgery can help shrink or eliminate tumors in people with triple-negative breast cancer (a type of breast cancer that lacks certain receptors). The goal is to see if this approach improves outcomes compared to the usual approach.
This trial tests whether giving a targeted drug before surgery can help shrink early-stage triple-negative breast cancer tumors. It may be an option for people who have not yet had any treatment for their breast cancer.
This trial tests whether adding an experimental drug called INBRX-106 to the standard immunotherapy (pembrolizumab) and chemotherapy before surgery can improve outcomes for patients with early-stage triple-negative breast cancer. The goal is to shrink the tumor and potentially reduce the risk of the cancer coming back.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.